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Peritransplant Ischemic Injury Is Associated
ith Up-Regulation of Stromal Cell-Derived Factor-1
ohamad H. Yamani, MD,* Norman B. Ratliff, MD,† Daniel J. Cook, PHD,§ E. Murat Tuzcu, MD,*
ang Yu, MS,* Robert Hobbs, MD,* Gustavo Rincon, MD,* Corinne Bott-Silverman, MD,*
ames B. Young, MD,* Nicholas Smedira, MD,‡ Randall C. Starling, MD, MPH*
leveland, Ohio
OBJECTIVES We evaluated chimerism and stromal cell-derived factor-1 (SDF-1) expression in response to
peritransplant ischemic injury following human heart transplantation.
BACKGROUND Myocardial ischemia has been shown to trigger mobilization of stem cells to the heart in
animal experiments.
METHODS Between January 1998 and April 2002, a total of 114 male recipients received hearts from
female donors. Of these 114 recipients, 26 had evidence of ischemic injury on their initial
heart biopsies (ischemia group). These were compared to the remaining 88 patients (control
group). Heart biopsy specimens obtained initially at one week and at one year after transplant
were evaluated from 20 matched patients of each group for the presence of Y chromosome-
containing nuclei. The SDF-1 messenger ribonucleic acid (mRNA) and protein expression
were also evaluated on initial heart biopsy specimens.
RESULTS At one week, Y chromosome-containing nuclei were significantly increased in the ischemia
group (0.68% vs. 0.04%; p  0.0001) compared to the control group. These were positive for
the stem cell factor receptor c-kit. A significant 3.3-fold increased mRNA expression (p 
0.001) and 2.8-fold increased protein expression (p  0.01) of SDF-1 was noted in the
ischemia group. At one year, Y chromosome was detected in 0.29% of cardiomyocyte nuclei
in the ischemia group but none in the control group. The ischemia group had poorer survival
and increased vasculopathy.
CONCLUSIONS This is the first report to describe chimerism and up-regulation of SDF-1 in human heart
transplantation in response to ischemic injury. (J Am Coll Cardiol 2005;46:1029–35)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.059© 2005 by the American College of Cardiology Foundation
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lxperimental evidence suggests that ischemic injury plays a
ivotal role in triggering mobilization of stem cells to the
ite of injury (1). Stem cells have been shown to contribute
o cardiac muscle repair and neovascularization after isch-
mic injury (2). Several endogenous and environmental
actors play important roles in regulation of stem cells,
ncluding inflammatory cytokines, growth factors, surface
eceptors, proteolytic enzymes, nuclear proteins, and stem
ell–host cell interaction (3). Stromal cell-derived factor-1
SDF-1), a member of the chemokine CXC subfamily, is
onsidered to play an important role in the trafficking of
ematopoietic stem cells to sites of ischemic injury and
ontributing to the process of neovascularization (4). Re-
ently, expression of SDF-1 has been shown to induce stem
ell homing to injured myocardium in an animal model of
yocardial infarction (5,6). Ischemic injury following car-
iac transplantation has been shown to be associated with
evelopment of vasculopathy and to portend a poor long-
erm outcome (7). Cardiac chimerism, caused by migration
f primitive cells from the recipient to the grafted heart, has
ecently been demonstrated in postmortem examinations (8)
nd in myocardial biopsies (9). However, the phenomenon
f stem cell mobilization and expression of SDF-1 in
From the Departments of *Cardiovascular Medicine, †Anatomic Pathology, and
Cardiothoracic Surgery, and the §Allogen Laboratory, Kaufman Center for Heart
ailure, Cleveland Clinic Foundation, Cleveland, Ohio.c
Manuscript received February 21, 2005; revised manuscript received April 24,
005, accepted April 25, 2005.esponse to peritransplant ischemic injury has not been
valuated before. We hypothesized that peritransplant isch-
mic injury triggers mobilization of stem cells to the
ransplanted heart and is associated with increased expres-
ion of SDF-1.
ETHODS
atient population. To study the process of cardiac chi-
erism in response to ischemic injury, patients with mis-
atched hearts were evaluated. Between January 1998 and
pril 2002, a total of 114 consecutive male recipients
eceived hearts from female donors. A group of 26 patients
ad evidence of ischemic injury on their initial heart
iopsies (ischemia group). Ischemic injury related to trans-
lantation was identified by areas of myocyte necrosis with
n absence of infiltration by activated lymphocytes or
acrophages. Their clinical outcome was compared to the
emaining 88 patients (control group). Patients underwent
erial heart biopsies and serial coronary angiograms as per
he surveillance heart transplant protocol. We collected five
iopsy specimens per patient and the sampling was done
rom the interventricular septum. Coronary artery stenosis
f 50% or greater in the absence of donor coronary athero-
clerosis was required for the diagnosis of transplant vascu-
opathy. The protocol was approved by the ethics review
ommittee of our institution.
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Peritransplant Ischemic Injury and SDF-1 September 20, 2005:1029–35luorescent in situ hybridization (FISH). To evaluate for
himerism over time, paired heart biopsy specimens, ob-
ained at one week and one year after transplant, were
valuated from 20 patients of the ischemia group. Paired
pecimens were not used in the remaining six patients
ecause one patient had severe rejection during the first
eek of transplantation and, therefore, was excluded from
issue analysis to avoid potential rejection-related bias; five
atients expired before the end of 12 months and, therefore,
o tissue was available at 1 year. The 20 patients in the
schemia group were matched, in relation to baseline char-
cteristics, to 20 patients from the control group who also
ad no acute rejection on their initial biopsies, and their
yocardial biopsies were compared. Fluorescent in situ
ybridization was used to determine the presence of X
hromosome using X Alpha Satellite (DXZ1) probe
Qbiogene, Irvine, California) and of Y chromosome
sing DNA probe CEP Y satellite III (Vysis, Downers
rove, Illinois) as previously described (8). Cell number
as determined by 4=,6-diamidine-2-phenylindole dihy-
able 1. Baseline Characteristics
Control
(n  88)
Ischemia
(n  26)
onor age (yrs) 36  15 39  14
ecipient age (yrs) 54  9 57  10
tiology of heart disease
ICM/DCM/congenital 47/40/1 15/11/0
onor cause of death
CVA/trauma/other 40/43/5 13/11/2
schemia time (min) 178  42 180  44
VAD 18 (20%) 6 (23%)
iabetes mellitus 16 (18%) 5 (19%)
ypertension 39 (44%) 11 (42%)
yperlipidemia 35 (40%) 10 (38%)
LA mismatch 4.7  1.4 4.4  1.5
RA 20% 5 (5.7%) 2 (7.7%)
MV status
DR/DR/DR/DR 16/25/19/28 5/7/5/9
MV disease 9 (10.2%) 3 (11.5%)
ean episodes of acute cellular
rejection grade 3A
1.5  1.1 1.3  1.2
mmunosuppression
rednisone  CSA  AZA 15 (17%) 5 (19.2%)
rednisone  CSA  MMF 39 (44.4%) 11 (42.3%)
rednisone  MMF  FK506 30 (34.1%) 9 (34.6%)
rednisone  CSA  everolimus (3.4%) 1 (3.9%)
rednisone  CSA  rapamycin 1 (1.1%) 0 (0%)
ZA  azathioprine; CMV  cytomegalovirus; CSA  cyclosporine; CVA 
erebrovascular accident; D  donor; DCM  dilated cardiomyopathy; HLA 
uman leukocyte antigen; ICM  ischemic cardiomyopathy; LVAD  left ventric-
Abbreviation and Acronyms
FISH  fluorescent in situ hybridization
mRNA  messenger ribonucleic acid
RT-PCR  reverse transcription-polymerase chain
reaction
SDF-1  stromal cell-derived factor-1s
lar assist device use as a bridge to transplant; MMF  mycophenolate mofetil; PRA
panel reactive antibody; R  recipient.rochloride (DAPI) staining (Vysis) (10). Two biopsy
pecimens from female-donor/female-transplant recipients
nd another three biopsy specimens from male-donor/male-
ransplant recipients were used as negative and positive
ontrols, respectively.
ell markers. Antibodies against c-kit, a stem cell factor
eceptor (11), were used to identify primitive cells (Vector
aboratories, Burlingame, California) on initial heart biopsy
pecimens at one week after transplantation (12). To deter-
ine the nature of cells at one year after transplantation,
ntibodies against cardiac myosin heavy chain (Chemicon,
emecula, California), smooth muscle alpha-actin (Sigma,
t. Louis, Missouri), factor VIII (Sigma), vimentin (Sigma),
D45RB (Dako, Carpinteria, California), and CD68
Dako) were used to identify myocytes, smooth muscle cells,
ndothelial cells, fibroblasts, lymphocytes, and macro-
hages, respectively. The immunoglobulin-G antibodies
onjugated with fluorescein isothiocyanate (Jackson Im-
uno Research, West Grove, Pennsylvania) were used as
econdary antibodies (12).
DF-1 expression. The SDF-1 mRNA and protein ex-
ressions were evaluated on initial heart biopsy specimens
sing TaqMan quantitative reverse transcription-
olymerase chain reaction (RT-PCR) (13) and Western
lot analysis (14), respectively, as previously described. The
ligonucleotide sequences of TaqMan probe and primers of
DF-1 were as follows: TaqMan probe, SDF-1-859T:
AGCAGCGCCCCTCCCAAGA; forward primer,
DF-1-837F: TCTTCAGACACTGAGGCTCCC; re-
erse primer, SDF-1-903R: TATCTGAGTGCCACA-
AGGCC. Rabbit antihuman SDF-1 antibody (Chemi-
on) was used for immunoblotting.
Biotinylated antihuman SDF-1 antibody (Peprotech,
ocky Hill, New Jersey) was used (dilution  1:100) for
mmunohistochemistry staining of heart biopsy specimens
xamined at one week after transplant.
XCR4 expression. We evaluated mRNA expression of
XCR4, a receptor for SDF-1, on the initial heart biopsy
pecimens using TaqMan quantitative RT-PCR as described
efore (13). The oligonucleotide sequences of TaqMan probe
nd primers of CXCR4 were as follows: TaqMan probe,
XCR4-P837: TTCTTCGCCTGTTGGCTGCC; for-
ard primer, CXCR4-F814: CCACAGTCATCCTCATC-
TG; reverse primer, CXCR4-R915: ACCCTT-
CTTGATGATTTCC.
tatistical analysis. Data are presented as mean  stan-
ard deviation. Categorical variables were compared by chi
able 2. Percentage of Y Chromosome-Containing Nuclei
Control Ischemia p Value
ne week 0.04  0.03% 0.68  0.12% 0.0001
ne year 0.07  0.06%* 1.25  0.39%† 0.0001
p  0.058, compared to one week, in control group. †p  0.001, compared to one
eek, in ischemia group.quare. The Fisher exact test was used when the sample size
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September 20, 2005:1029–35 Peritransplant Ischemic Injury and SDF-1f the categorical variable was five or less, such as etiology of
eart disease (congenital), donor cause of death (other),
iabetes mellitus, panel reactive antibody, cytomegalovirus
isease, and immunosuppression. Continuous variables
ere compared using the Wilcoxon rank sum test. Differ-
nces were considered significant at p  0.05. Survival and
reedom from vasculopathy were assessed by construction of
aplan-Meier plots and calculation of the log-rank chi-
quare statistic.
ESULTS
oth groups had similar baseline characteristics (Table 1).
wo patients in the ischemia group had evidence of mild
eft ventricular dysfunction (left ventricular ejection fraction
0% and 45%, respectively) soon after transplantation that
ecovered within one week.
ISH. The female-donor/female-recipient biopsies
howed no evidence of Y chromosome and the male-donor/
ale-recipient biopsies showed evidence of Y chromosome
n 46% of the 2,000 nuclei studied, yielding a sensitivity and
pecificity comparable to other studies (8,9,15). The isch-
mia group had significant increased proportion of Y
hromosome-containing nuclei compared to the control
roup, at both one week and one year after transplantation
Table 2). These cells included all cells that contained the Y
hromosome and were positive for c-kit marker, suggesting
tem cell in origin (Fig. 1). The increase in the proportion
igure 1. Fluorescent in situ hybridization and double immunofluoresc
lue-stained nuclei containing Y chromosome (arrows) in green (A). (B) Thigure 2. A heart biopsy specimen from the control group, obtained at one year a
B) in red. Y chromosome (arrows) is detected in green.f Y chromosome-containing nuclei from one week to one
ear was also significant in the ischemia group (Table 2).
one of the patients in the control group had evidence of
himerism in the cardiomyocytes on their biopsies. The Y
hromosome was detected only in lymphocytes and macro-
hages in this group of patients (Fig. 2). However, in the
schemia group, Y chromosome was detected in 0.29 
.19% of 49,421 cardiomyocyte nuclei evaluated (Fig. 3).
o 3-X chromosomes were identified in the nuclei, thus
xcluding the possibility of cell fusion as an explanation for
he chimerism phenomenon observed. In addition to infil-
rating cells, such as lymphocytes, macrophages, and fibro-
lasts, Y chromosome was detected also in vascular smooth
uscle cells (0.12  0.09%) and capillary endothelial cells
0.08  0.07%) in the ischemia group (Fig. 4).
DF-1 expression. Compared to the control group, the
schemia group had significant increased protein expression
2.8-fold; p 0.01) (Figs. 5 and 6) and significant increased
RNA expression (3.3-fold; p  0.001) (Fig. 7) of SDF-1,
uggesting the presence of up-regulation of SDF-1 in
esponse to ischemic injury. Interestingly, the highest level
f chimerism in the myocytes (0.56  0.53%) was noted in
subgroup of four patients who had greater than three-fold
ncreased protein expression of SDF-1.
XCR4 expression. Compared to the control group, the
schemia group had significantly increased mRNA expres-
ion of CXCR4 (3.1-fold; p  0.001), suggesting the
of initial heart biopsy specimen from ischemia group showing DAPI
ells are positive for c-kit in red (arrowheads), suggestive of stem cell origin.encefter transplantation, showing immunostaining for CD45RB (A) and CD68
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Peritransplant Ischemic Injury and SDF-1 September 20, 2005:1029–35resence of up-regulation of this receptor to SDF-1 in
esponse to ischemic injury.
asculopathy and survival. The ischemia group had in-
reased angiographic evidence of transplant vasculopathy
Fig. 8). At one year, three patients in the ischemia group,
ut none in the control group, had evidence of graft
ysfunction (p  0.01). The left ventricular ejection frac-
ions were 35%, 40%, and 45%, respectively. Freedom from
asculopathy was 41% in the ischemia group compared to
5% in the control group (Fig. 8) at five years (p  0.001).
urther, the ischemia group experienced worse four-year
urvival (Fig. 8), 64% versus 85% (p  0.047).
ISCUSSION
ur study has three main findings. First, ischemic injury is
ssociated with increased chimerism. Second, ischemic in-
ury is associated with up-regulation of SDF-1 and its
eceptor, CXCR4. Third, ischemic injury is associated with
orse vasculopathy and survival.
Mobilization of stem cells has been described in animal
igure 3. A heart biopsy specimen from the ischemia group, obtained at
ne year after transplantation, showing immunostaining for myosin heavy
hain. Y chromosome is detected (arrow) in a cardiomyocyte nucleus.
igure 4. Heart biopsy specimens from the ischemia group, obtained at
lpha-actin (A) and factor VIII (B). Y chromosomes (arrows) are detected in vasc
ndothelial cell (B).odels of ischemia (1–6). Following experimental myocar-
ial infarction, stem cells migrate to the damaged area in an
ttempt to promote repair and contribute to regeneration of
schemic cardiac muscle and vascular endothelium (10).
hese stem cells could have originated directly from the
one marrow and implanted the heart, or circulating hema-
opoietic cells could have homed to the heart (8,10,16).
ardiac chimerism has been reported in response to chronic
ejection in the rat transplant model (17). The investigators
oted that the majority of the stem cells exhibited fibroblast
henotypes. Our study reports chimerism in response to
nother phenomenon, an ischemia-induced myocardial in-
ury, a well defined histopathologic pattern, observed soon
fter transplantation (18,19). Several factors play a role in
he pathogenesis of ischemic injury, including hemody-
amic status of the donor, inotropic support required by the
onor, graft ischemia time, the quality of graft preservation,
nd myocardial damage due to reperfusion (20). As a result,
njured endothelial cells could, in turn, promote atheroscle-
osis through a number of mechanisms including release of
rowth factors and cytokines, platelet adhesion, expression
f adhesion molecules, and proliferation of vascular smooth
uscle cells (21). The phenomenon of chimerism in trans-
lanted human hearts has been a subject of controversy (22).
ome investigators found no evidence for chimerism in the
ardiac myocytes (15,23,24) or reported a low level of
himerism, an average of 0.04% of cardiomyocytes, mostly
n association with regions of acute rejection (25). However,
ther investigators have reported a higher degree of chimer-
sm, 0.16% (9) and 9% (8) in the cardiomyocytes. Several
actors have been proposed as an explanation of this varia-
ion in results, including methodology, limitations of the
easurements, timing of the observations, and the criteria
sed to identify chimerism (22). In our study, we evaluated
atients at two specific points of time to exclude the timing
actor as a confounding variable. The sensitivity and speci-
city of our technique was comparable to others. We also
xcluded patients with acute rejection during the first week to
void this potential bias as suggested by some investigators
year after transplantation, showing immunostaining for smooth muscleone
ular smooth muscle cell nuclei in intramyocardial arteriole (A) and capillary
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September 20, 2005:1029–35 Peritransplant Ischemic Injury and SDF-122). We noted a significant increase in the Y chromosome-
ontaining nuclei from one week to one year in the ischemia
roup. However, we cannot determine from our study when
he peak of chimerism has occurred. It has been reported
hat the highest level of chimerism in myocytes, 15%, was
oted between 4 and 28 days after transplantation (8).
urther, it is possible that some of the stem cells could have
ndergone apoptosis in the interim period. Our findings of
himerism in the cardiomyocytes in patients with ischemic
njury and its absence in the control group suggest that
schemia plays a key role in triggering mobilization of stem
ells to the site of injury. This phenomenon may represent
nother factor that explains the variation in results reported
mong different investigators regarding speculation about
he presence or absence of chimerism in the myocytes.
The increased expression of the chemokine SDF-1 and
ts receptor, CXCR4, is another major finding of our study.
oth CXCL1 and CXCL5 are among the chemokine genes
oted to be highly induced in the early phase in response to
schemia reperfusion injury in animal models of cardiac
ransplantation (26). In earlier studies, a dual pattern of
Figure 5. Stromal cell-derived factor-1 immunohistochemistry of init
igure 6. Stromal cell-derived factor-1 (SDF-1) immunoblotting showing
ncreased myocardial protein expression (normalized to glyceraldehyde
hospho dehydrogenase [GAPDH]) in the presence of ischemic injury (I)p
ompared to the control group (C). Liver cirrhotic tissue was used as a
ositive control.hemokine induction was reported in response to ischemia-
eperfusion injury: an early phase of macrophage inflamma-
ory protein-2 and monocyte chemoattractant protein-1
roduction and a late phase of lymphotactin, RANTES
regulated upon activation normal T-cell expressed and
ecreted), and interferon-inducible protein-10 expression,
hich correlated with the subsequent development of car-
iac allograft vasculopathy (27,28). The SDF-1 interaction
ith its receptor, CXCR4, is reported to play an important
ole in numerous biological processes including hematopoi-
sis, cardiogenesis, vasculogenesis, neuronal development,
nd immune cell trafficking (29). SDF-1 is up-regulated in
ypoxic tissues (30) and may represent a physiologically
elevant chemoattractant for the recruitment of circulating
rogenitor cells to sites of ischemia (4,31). It is expressed in
yocytes (32), vascular endothelial cells (33), and fibroblasts
34).
The SDF-1 has been shown to modulate the homing of
tem cells to its site by mediating chemotaxis (35). The
ffect of SDF-1 on stem cell homing and tissue regeneration
n animal models of myocardial infarction has been recently
ell illustrated (5,6). The systemic overexpression of SDF-1
o induce stem cell mobilization has been described (5,36–
8). In human cardiac transplantation, SDF-1 was found to
lay no significant role in allograft rejection (32). Our study
ighlights the functional role of SDF-1 in response to
schemic injury; the highest level of chimerism in myocytes
as in the subgroup of patients who had a greater than
hree-fold increase in protein expression of this chemokine.
We have previously shown that ischemic injury is associated
ith increased progression of allograft coronary vasculopathy
nd poorer survival (7). The present study confirms similar
oor clinical outcome in gender-mismatched hearts in
esponse to ischemic injury. Immune and nonimmune
actors have been implicated in the pathogenesis of cardiac
llograft vasculopathy (39,40). We have previously shown
p-regulation of v3 (vitronectin receptor) and tissue
actor, activation of the matrix metalloproteinase induction
ystem, and increased myocardial fibrosis in response to
eritransplant ischemic injury (14) that may contribute to
he subsequent development of allograft vasculopathy. The
art biopsy specimens from the control (A) and ischemia (B) groups.resent study adds to these observations. In summary,
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group demonstrates a shift of the mRNA curve to the left, indicating an earlier thr
expression of SDF-1. Rn  change in ribonucleic acid acitivity.
Figure 8. Kaplan-Meier curves of freedom from vasculopathy (A) and
survival (B) in the control (solid line) and ischemia (dashed line) groups.
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Peritransplant Ischemic Injury and SDF-1 September 20, 2005:1029–35eritransplant ischemic injury induces a complex array of
esponses, including chimerism and increased cardiac ex-
ression of SDF-1. It is also associated with increased
asculopathy and diminished survival. Whether poor out-
ome is related to insufficient stem cell recruitment or
elated to a direct effect of stem cell mobilization can not be
oncluded from this study, because chimerism is not a
elective process, its presence in the myocytes may
ntuitively suggest an attempt for a regenerative process,
ut its presence in the inflammatory cells and vasculature
ay suggest an adverse impact on allograft vasculopathy.
echanistic studies are required to address these impor-
ant issues.
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